Panel Discussion: De-Risking mRNA Innovation to Attract Investment & Partnerships in a Post-Vaccine Era

• What makes an mRNA therapeutic platform fundable in 2026? What clinical and strategic proof do VCs want to see?
• How are biotech leaders navigating delivery licensing limitations, high COGS, and regulatory uncertainty to stay attractive to partners?
• Are non-US trial strategies, earlier pharma engagement, or new reimbursement models the key to investor re-engagement?

Speakers:

Maciej Drożdż

Former Venture Capital Investor, Founder & Chief Executive Officer

MiMo Biotech

Marek Kozlowski

Senior Investment Director

NRW.BANK

Alessio D’addabbo

Analyst

Syncona